Fig. 2

Distinct profiles of CTA/SALL4 and AFP-specific T cell response in different stages of HCC. The magnitude of T cell response against indicated antigens (including AFP, SALL4, MAGE-A1, MAGE-A3, NY-ESO-1 and SSX-2) in HCC patients with 0/A (25 subjects) (A) or B/C (33 subjects) stage (B). The T cell response magnitude (right) and the recognition frequency (left) to each kind of tumour antigen in HCC patients with BCLC-0/A (white, 25 subjects) and BCLC-B/C stage (black, 33 subjects) were presented and compared in (C). (D), Proportion of stage of HCC patients in two distinct tumour antigen specific T cell response combinations. CTAs & SALL4-specific T cell response was defined as “+” if one antigen was recognized by PBMCs at least. Non-parametric test was used to compare the response magnitude of patients in different stages, and chi-square test was used to compare the recognition frequencies